Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer's Disease
Wednesday, May 6, 2026
7:00 PM – 8:00 PM China CST (UTC+8)
8:00 PM – 9:00 PM Japan JST (UTC+9)
7:00 AM – 8:00 AM ET (UTC-4)
Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: Asia | Target Audience: Neurologists and Psychiatrists
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: March 19, 2026
EXPIRATION DATE: March 19, 2027
Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: United States | Target Audience: Neurologists and Psychiatrists
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: March 19, 2026
EXPIRATION DATE: March 19, 2027
Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients with Alzheimer’s Disease
Region: Europe | Target Audience: Neurologist and Psychiatrists
This enduring activity brings together leading experts across multiple disciplines to advance practical knowledge in recognizing, monitoring, and managing amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease receiving anti-amyloid therapies (AATs). Through case-based discussion, evidence-driven updates, and multidisciplinary perspectives, the program focuses on improving confidence in ARIA identification, optimizing collaborative workflows across care settings, and strengthening patient-centered communication and shared decision-making to support safe and effective treatment.
RELEASED DATE: March 19, 2026
EXPIRATION DATE: March 19, 2027
DETECT— Engaging Patients, Caregivers, and Multidisciplinary Providers in the Shared Goal of Facilitating an Earlier Alzheimer’s Disease Diagnosis and Optimizing the Use of Anti-Amyloid Therapies
Treatment Topic: Optimizing the Use of Anti-Amyloid Therapy for Early Asymptomatic AD
This case-based educational enduring activity is designed to help Alzheimer’s disease and dementia healthcare providers optimize the use of anti-amyloid therapy for early Alzheimer’s disease. Through interactive case-based learning, our faculty will assist learners in developing strategies to improve multidisciplinary and clinician/patient communication skills to facilitate the best possible treatment outcomes.
RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026
DETECT— Engaging Patients, Caregivers, and Multidisciplinary Providers in the Shared Goal of Facilitating an Earlier Alzheimer’s Disease Diagnosis and Optimizing the Use of Anti-Amyloid Therapies
Part 2: Optimizing the Use of Anti-Amyloid Therapy for Early Asymptomatic AD
This two-part case-based educational grand rounds activity is designed to enhance the capabilities of healthcare providers in managing Alzheimer’s disease and related dementias. Part two will equip learners with strategies to optimize the use of amyloid-targeting therapies and improve multidisciplinary collaboration and clinician-patient communication to achieve the best possible treatment outcomes.
RELEASED DATE: November 12, 2025
EXPIRATION DATE: November 12, 2026
DETECT— Engaging Patients, Caregivers, and Multidisciplinary Providers in the Shared Goal of Facilitating an Earlier Alzheimer’s Disease Diagnosis and Optimizing the Use of Anti-Amyloid Therapies
Part 1: Facilitating Earlier Diagnosis of Alzheimer's Disease
This two-part case-based educational grand rounds activity is designed to enhance the capabilities of healthcare providers in managing Alzheimer’s disease and related dementias. Part one focuses on early diagnosis of AD through comprehensive history and physical examinations, quantitative assessments, neuroimaging, and appropriate referrals.
RELEASED DATE: October 31, 2025
EXPIRATION DATE: October 31, 2026
DETECT— Engaging Patients, Caregivers, and Multidisciplinary Providers in the Shared Goal of Facilitating an Earlier Alzheimer’s Disease Diagnosis and Optimizing the Use of Anti-Amyloid Therapies
Facilitating an Earlier Alzheimer’s Disease Diagnosis
This case-based educational activity is designed to help Alzheimer’s disease and dementia providers diagnose AD earlier in the disease course through comprehensive history and physical, validated cognitive assessments, neuroimaging, and referral, when appropriate. Through interactive case-based learning, our faculty will assist learners in developing strategies to improve multidisciplinary care and clinician/patient communication to facilitate the best possible treatment outcomes.
RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026
DETECT— Navigating a New Era in Alzheimer’s Disease: Integrating Disease-Modifying Therapies into Clinical Practice
In this enduring grand rounds program, we will provide instruction on screening, diagnosing, and staging of mild cognitive impairment and Alzheimer's disease. The lecture and case-based scenarios will educate on the appropriate use of disease-modifying therapy, assessing and managing adverse events associated with these therapies, and implementing tools to solve issues with access to therapy. Finally, the faculty will discuss shared decision making and multidisciplinary teams as essential elements for successful care of these patients.
RELEASED DATE: May 15, 2025
EXPIRATION DATE: May 15, 2026
DETECT— Navigating a New Era in Alzheimer’s Disease: Integrating Disease-Modifying Therapies into Clinical Practice
This four-episode podcast is designed to identify and analyze the educational needs and practice gaps that exist among healthcare practitioners who are involved in the diagnosis and management of patients with Alzheimer’s disease. This program will educate participants on providing a timely diagnosis, referral, and appropriate treatment. We will hear from a primary care physician, a neurologist, a geriatrician, and a geriatric psychiatrist on the importance of multidisciplinary care and shared decisions in the diagnosis and treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD).
RELEASED DATE: April 25, 2025
EXPIRATION DATE: May 16, 2026
